[
    [
        {
            "time": "",
            "original_text": "长春高新：公司生长激素产品目前主要在国内销售",
            "features": {
                "keywords": [
                    "长春高新",
                    "生长激素",
                    "国内销售"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "长春高新：公司生长激素产品目前主要在国内销售",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "长春高新控股子公司获药品补充申请批件并成药品上市许可持有人",
            "features": {
                "keywords": [
                    "长春高新",
                    "控股子公司",
                    "药品补充申请",
                    "上市许可"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "长春高新控股子公司获药品补充申请批件并成药品上市许可持有人",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：医美行业强化监管 安徽省IVD集采结果公布",
            "features": {
                "keywords": [
                    "医药生物",
                    "医美行业",
                    "强化监管",
                    "安徽省IVD集采"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业周报：医美行业强化监管 安徽省IVD集采结果公布",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "长春高新(000661.SZ)子公司华康药业成为小儿健胃宁口服液等药品上市许可持有人",
            "features": {
                "keywords": [
                    "长春高新",
                    "华康药业",
                    "小儿健胃宁口服液",
                    "上市许可"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "长春高新(000661.SZ)子公司华康药业成为小儿健胃宁口服液等药品上市许可持有人",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "长春高新：子公司6个药品获得药品补充申请批件",
            "features": {
                "keywords": [
                    "长春高新",
                    "子公司",
                    "药品补充申请",
                    "批件"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "长春高新：子公司6个药品获得药品补充申请批件",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药与健康护理行业月报：智飞生物新冠疫苗III期数据优异 对变异株仍然有效",
            "features": {
                "keywords": [
                    "医药",
                    "健康护理",
                    "智飞生物",
                    "新冠疫苗",
                    "III期数据",
                    "变异株"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药与健康护理行业月报：智飞生物新冠疫苗III期数据优异 对变异株仍然有效",
                "Correlation": 2,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]